- In July 2023, Granules India Limited received approval from the U.S. FDA for its Acetaminophen and Ibuprofen combination tablets, intended for treating headaches, minor arthritis pain, and toothaches. This approval enables Granules India to strengthen its product portfolio in the high-demand U.S. market, enhancing its credibility in regulated markets. The move is expected to boost ibuprofen API demand due to increased production requirements for the approved formulation
- In February 2023, Univar Solutions Brasil Ltd. entered into a distribution agreement with SI Group to expand its ibuprofen offerings in Brazil. This partnership is aimed at improving market penetration and product availability across Latin America. By reinforcing supply chain networks and local distribution capabilities, this move is likely to accelerate ibuprofen API consumption in one of the region’s growing pharmaceutical markets
- In November 2022, Solara Active Pharma Sciences Limited secured a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for its ibuprofen API produced at its Vishakhapatnam facility in Andhra Pradesh, India. This regulatory milestone opens up export opportunities to Europe, a market with stringent quality requirements, positioning Solara as a competitive global supplier and contributing to the broader expansion of the ibuprofen API market
- In March 2022, Lonza announced a USD 935 million investment in new API manufacturing facilities in Portsmouth, New Hampshire, and Visp, Switzerland, and completed a laboratory expansion at its site in Nansha, China. These infrastructure developments aim to significantly scale up API production capacity and operational capabilities across three strategic regions. The investments are expected to support growing global demand for ibuprofen and other APIs, improving supply resilience and geographic accessibility
- In August 2021, Alkem Laboratories launched a combination of ibuprofen and famotidine tablets in the U.S., targeting the treatment of symptoms related to rheumatoid arthritis and osteoarthritis. This product launch reflects the increasing need for advanced, combination-based pain management therapies and is expected to stimulate demand for ibuprofen APIs used in chronic inflammatory conditions
